Research programme: Axl receptor tyrosine kinase inhibitors - Astex Pharmaceuticals

Drug Profile

Research programme: Axl receptor tyrosine kinase inhibitors - Astex Pharmaceuticals

Alternative Names: Axl-9; SGI-AXL-277

Latest Information Update: 19 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 15 Mar 2012 Discontinued for Haematological malignancies in USA (unspecified route)
  • 23 May 2007 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007)
  • 01 Dec 2006 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top